User login
Key clinical point: Patients with early rheumatoid arthritis (ERA) receiving treat-to-target management did not have an excess 5-year risk for cardiovascular events (CVE) compared with risk factor-matched non-RA control individuals.
Major finding: Over 5 years, the risk for incident CVE was comparable among patients with ERA and matched non-RA control individuals (hazard ratio [HR] 0.53; P = .3), but significantly higher among patients with historical RA (HRA) receiving routine care vs matched non-RA control individuals (HR 1.95; P = .009).
Study details: The data come from an observational case-control study including patients with ERA (n = 261) receiving treat-to-target management and patients with HRA (n = 268) receiving routine care, each of whom were cardiovascular risk factor-matched to 3 non-RA control individuals.
Disclosures: This study did not receive any specific funding. The authors declared no conflicts of interest.
Source: Lam TO et al. Five-year cardiovascular event risk in early rheumatoid arthritis patients who received treat-to-target management: A case-control study. Rheumatology (Oxford). 2023 (Jan 27). Doi: 10.1093/rheumatology/kead039
Key clinical point: Patients with early rheumatoid arthritis (ERA) receiving treat-to-target management did not have an excess 5-year risk for cardiovascular events (CVE) compared with risk factor-matched non-RA control individuals.
Major finding: Over 5 years, the risk for incident CVE was comparable among patients with ERA and matched non-RA control individuals (hazard ratio [HR] 0.53; P = .3), but significantly higher among patients with historical RA (HRA) receiving routine care vs matched non-RA control individuals (HR 1.95; P = .009).
Study details: The data come from an observational case-control study including patients with ERA (n = 261) receiving treat-to-target management and patients with HRA (n = 268) receiving routine care, each of whom were cardiovascular risk factor-matched to 3 non-RA control individuals.
Disclosures: This study did not receive any specific funding. The authors declared no conflicts of interest.
Source: Lam TO et al. Five-year cardiovascular event risk in early rheumatoid arthritis patients who received treat-to-target management: A case-control study. Rheumatology (Oxford). 2023 (Jan 27). Doi: 10.1093/rheumatology/kead039
Key clinical point: Patients with early rheumatoid arthritis (ERA) receiving treat-to-target management did not have an excess 5-year risk for cardiovascular events (CVE) compared with risk factor-matched non-RA control individuals.
Major finding: Over 5 years, the risk for incident CVE was comparable among patients with ERA and matched non-RA control individuals (hazard ratio [HR] 0.53; P = .3), but significantly higher among patients with historical RA (HRA) receiving routine care vs matched non-RA control individuals (HR 1.95; P = .009).
Study details: The data come from an observational case-control study including patients with ERA (n = 261) receiving treat-to-target management and patients with HRA (n = 268) receiving routine care, each of whom were cardiovascular risk factor-matched to 3 non-RA control individuals.
Disclosures: This study did not receive any specific funding. The authors declared no conflicts of interest.
Source: Lam TO et al. Five-year cardiovascular event risk in early rheumatoid arthritis patients who received treat-to-target management: A case-control study. Rheumatology (Oxford). 2023 (Jan 27). Doi: 10.1093/rheumatology/kead039